ANCON Medical

United Kingdom
Canterbury, England, United Kingdom, CT2 7FG

Company profile

ANCON Medical company profile

ANCON Medical is a subsidiary of ANCON Technologies and is a medical device maker of non-invasive disease screening technology. Ancon Medical ’s primary technology is the Nanoparticle Biomarker Tagging (NBT), which gives medical technicians a simple breath screening device that operates at unprecedented levels of sensitivity. Ancon Medical’s team of engineers, scientists and business experts have been developing NBT technology, establishing an impressive portfolio of patents and intellectual property in both the U.S. and U.K. The technology has been designed to be compatible with, and deliverable to, point of care clinics. Our company presents unique solutions for the healthcare industry, providing a pathway to early detection capabilities that can be critical for treating deadly illnesses, such as lung cancer, tuberculosis and others. Early diagnosis is often crucial to providing effective healthcare, increasing a patient’s chances of recovery and improving their quality of life. From close working relationships with global market leaders and renowned public and private laboratories, Ancon Medical has received numerous grants and awards from public bodies. Recently Ancon has been awarded funding from the Technology Strategy Board in the UK and successfully demonstrated potential of the NBT technology to early diagnosis of tuberculosis and lung cancer. Ancon Medical has two world locations. The facility in Minnesota (USA) is part of the state’s Medcal Alley medical device manufacturing community, and the same facilities in Kent (UK) operate within the Innovation Centre located within the grounds of the University of Kent at Canterbury.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2014-06-12

Headquarters

Postal code
CT2 7FG
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
2
Total equity funding
$2.9M
Last funding
Seed / $1.3M / 2017-10-01
Last equity funding
Seed / $1.3M
Founders
2
Articles
45

Founders and investors

Founders

Dr Boris GorbunovDr Robert Muir